녹내장 환자들에게 미세파동 경공막 섬모체 광응고술을 이용한 치료의 결과

Abstract

Purpose : To evaluate the effectiveness, safety and application range of micropulse transscleral cyclophotocoagulation (MP-TSCPC) for glaucoma patients.

Subjects and Methods : This was a retrospective study. Seventy-four (74) eyes of 53 glaucoma patients who had been treated with MP-TSCPC between July and December 2018 were reviewed. Preoperative and postoperative clinical characteristics were collected and their changes were analyzed. The MP-TSCPC survival rate was calculated, and multivariate logistic regression analysis was performed to determine the significant factors related to MP-TSCPC failure.

Results : The mean follow-up time was 415 days, and the mean intraocular pressure (IOP) was decreased significantly, from 22.6 ± 6.6 to 15.9 ± 5.3 mmHg at the final visit. The number of topical medications also was significantly decreased. There were no severe postoperative complications such as hypotony, phthisis bulbi or severely decreased visual acuity (VA). The probability of notrequiring MP-TSCPC retreatment was 90% at postoperative 3 months and 80% at 1 year. In a multivariate logistic analysis, glaucoma stage was identified as a significant factor related to MP-TSCPC failure. Advanced-glaucoma-stage eyes had a significantly lower odds ratio of failure than did early-glaucoma-stage eyes (OR: 0.23, 95% CI: 0.06-0.87, p=0.029).

Conclusions : MP-TSCPC is an effective and safe procedure not only for refractory glaucoma patients but also for patients who show advanced-stage glaucoma with good VA.